NCT02653976View on ClinicalTrials.gov

A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

March 25, 2016

Primary Completion Date

October 11, 2020

Study Completion Date

June 17, 2021

Conditions
Peripheral T-Cell Lymphoma
Interventions
DRUG

SP-02L (darinaparsin for injection)

Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days

Trial Locations (24)

Unknown

Hong Kong

Nagoya

Yoshida-gun

Isehara

Yokohama

Sendai

Suita

Chuo-ku

Koto-ku

Minato-ku

Fukuoka

Gifu

Okayama

Goyang-si

Hwasun-gun

Gangnam-gu

Nowon-gu

Seodaemun-gu

Songpa-gu

Beitou

Zhongzheng

Taichung

Tainan City

Taoyuan District

Sponsors
All Listed Sponsors
lead

Solasia Pharma K.K.

INDUSTRY